Investing.com - Biogen (NASDAQ: BIIB) reported first quarter EPS of $3.40, $0.12 better than the analyst estimate of $3.28. Revenue for the quarter came in at $2.46B versus the consensus estimate of $2.34B.
Guidance
Biogen sees FY 2023 EPS of $15.00-$16.00 versus the analyst consensus of $15.48.
Biogen's stock price closed at $293.03. It is up 0.38% in the last 3 months and up 41.57% in the last 12 months.
Biogen saw 1 positive EPS revisions and 11 negative EPS revisions in the last 90 days. See Biogen's stock price’s past reactions to earnings here.
According to InvestingPro, Biogen's Financial Health score is "good performance".
Check out Biogen's recent earnings performance, and Biogen's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar